Breaking News, Collaborations & Alliances

Pyxis Oncology to Acquire Apexigen in $16M Deal

Adds humanized antibody generation to its Flexible Antibody Conjugation Technology (FACT) ADC toolkit acquired from Pfizer.

Pyxis Oncology, Inc., a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, and Apexigen, Inc., a clinical-stage biopharmaceutical company focused on developing antibody therapeutics for oncology, entered a definitive agreement by which Pyxis Oncology will acquire Apexigen for a total enterprise value of approximately $16 million. “This acquisition uniquely positions Pyxis Oncology at the forefront of antibody-drug conjugate (ADC) in...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters